Organovo (NASDAQ:ONVO) Earns Sell Rating from Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Organovo (NASDAQ:ONVO) in a research report issued on Wednesday. The firm set a “sell” rating on the medical research company’s stock.

Organovo Stock Up 1.4 %

NASDAQ ONVO opened at $0.43 on Wednesday. The business’s 50-day moving average price is $0.44 and its 200 day moving average price is $0.63. The firm has a market cap of $6.56 million, a P/E ratio of -0.40 and a beta of 0.62. Organovo has a 52-week low of $0.32 and a 52-week high of $1.74.

Institutional Trading of Organovo

An institutional investor recently bought a new position in Organovo stock. Armistice Capital LLC purchased a new stake in Organovo Holdings, Inc. (NASDAQ:ONVO) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 929,000 shares of the medical research company’s stock, valued at approximately $708,000. Armistice Capital LLC owned approximately 6.46% of Organovo at the end of the most recent reporting period. Institutional investors own 8.23% of the company’s stock.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.